BCL2 and cancer: Mechanistically, the activation of the markers of apoptosis Bax, Bcl2 and TP53, as well as the TUNEL assay strongly suggest that the combined treatment lead to apoptotic death of the cancer cells and the selection of the “healthy”, hepatocyte-like cells since we found an increase of the mature hepatocyte markers ORM2 and CYP3A4 in cells with combined treatments.